During the launch of Bevacizumab, a biosimilar of Avastin, Dr Himanshu Gadgil, CEO, Enzene Biosciences Ltd stated that one of the problems they were trying to solve was to disrupt the cost barriers in the biosimilars market because India has been developing biosimilars for quite some time but the affordability has remained a big concern., During the launch of Bevacizumab, a biosimilar of Avastin, Dr Himanshu Gadgil, CEO, Enzene Biosciences Ltd stated that one of the problems they were trying to solve was to disrupt the cost barriers in the biosimilars market because India has been developing biosimilars for quite some time but the affordability has remained a big concern., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way